Welcome to the Products Liability website! We are an open, friendly and diverse Committee, combining lawyers of all ages and backgrounds, who come from around the country and work in different practice settings. We are not so large that you will feel lost in the crowd; and large enough with enthusiasm to spare to mount significant CLE programs and other member benefits.
If you have an interest in national, regional or local program planning, publishing articles about the law, creating online columns or CLE, and would like to work with a highly collegial and diverse group of lawyers with interests in products liability law and practice, then you've come to the right Committee!
The Spring 2009 edition of the Products Liability newsletter is now available.
On March 4, 2009, the United States Supreme Court issued its long-awaited opinion in Wyeth v. Levine. This case was the most recent in the ongoing debate over federal preemption in the area of pharmaceutical and medical device products. Here, Wyeth presented a fundamental issue: does Food and Drug Administration (FDA) approval of a drug’s label preempt common law tort claims? By a 6-3 vote, the Supreme Court held that FDA approval of a drug label does not preempt state law tort claims.
This article highlights and summarizes landmark products liability cases decided in 2008, as well as pertinent new statutes and regulatory activity, as presented during the always popular year-in-review products liability breakout session at the 2009 Joint CLE Seminar in Vail, Colorado.

